These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7885342

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P, Lévesque M, Parent A.
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Olivopontocerebellar atrophy and Parkinson's disease: diagnostic problems].
    Rodríguez M, Artieda J, Zubieta JL, Obeso JA.
    Neurologia; 1994 Jan; 9(1):4-11. PubMed ID: 8161468
    [Abstract] [Full Text] [Related]

  • 6. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y.
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [3H]DOPA formed from [3H]tyrosine in living rat brain is not committed to dopamine synthesis.
    Cumming P, Ase A, Kuwabara H, Gjedde A.
    J Cereb Blood Flow Metab; 1998 May; 18(5):491-9. PubMed ID: 9591841
    [Abstract] [Full Text] [Related]

  • 10. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS, Tang LL, Zheng SS, Zhan RY, Zhou YQ, Goudreau J, Kaufman D, Chen AF.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):155-61. PubMed ID: 15790539
    [Abstract] [Full Text] [Related]

  • 11. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T.
    Exp Neurol; 2004 Jul 24; 188(1):65-73. PubMed ID: 15191803
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies.
    Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D.
    J Neural Transm Suppl; 1978 Jul 24; (14):121-31. PubMed ID: 39974
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [The changes of striatal dopamine levels in the brain in rat models for Parkinson's disease after gene therapy].
    Tong H, Zhang J, Xu Q.
    Zhonghua Yi Xue Za Zhi; 1996 Jul 24; 76(7):490-2. PubMed ID: 9275495
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
    Jakowec MW, Nixon K, Hogg E, McNeill T, Petzinger GM.
    J Neurosci Res; 2004 May 15; 76(4):539-50. PubMed ID: 15114626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.